Analysis by use of the McNemar test of patients who upgraded or downgraded their response status after consolidation therapy with VTD or TD
| Response status before consolidation . | Response status after consolidation . | |||||
|---|---|---|---|---|---|---|
| VTD . | TD . | |||||
| CR (N) . | < CR (N) . | Total (N) . | CR (N) . | < CR (N) . | Total (N) . | |
| CR | 72 | 6 | 78 | 59 | 6 | 65 |
| < CR | 25 | 57 | 82 | 16 | 80 | 96 |
| Total | 97 | 63 | 160 | 75 | 86 | 161 |
| P | .0009 | .0525 | ||||
| Response status before consolidation . | Response status after consolidation . | |||||
|---|---|---|---|---|---|---|
| VTD . | TD . | |||||
| CR (N) . | < CR (N) . | Total (N) . | CR (N) . | < CR (N) . | Total (N) . | |
| CR | 72 | 6 | 78 | 59 | 6 | 65 |
| < CR | 25 | 57 | 82 | 16 | 80 | 96 |
| Total | 97 | 63 | 160 | 75 | 86 | 161 |
| P | .0009 | .0525 | ||||
| Response status before consolidation . | CR/nCR (N) . | < nCR (N) . | Total (N) . | CR/nCR (N) . | < nCR (N) . | Total (N) . |
|---|---|---|---|---|---|---|
| CR/nCR | 95 | 6 | 101 | 77 | 11 | 88 |
| < nCR | 22 | 37 | 59 | 21 | 52 | 73 |
| Total | 117 | 43 | 160 | 98 | 63 | 161 |
| P | .0037 | .1102 | ||||
| Response status before consolidation . | CR/nCR (N) . | < nCR (N) . | Total (N) . | CR/nCR (N) . | < nCR (N) . | Total (N) . |
|---|---|---|---|---|---|---|
| CR/nCR | 95 | 6 | 101 | 77 | 11 | 88 |
| < nCR | 22 | 37 | 59 | 21 | 52 | 73 |
| Total | 117 | 43 | 160 | 98 | 63 | 161 |
| P | .0037 | .1102 | ||||
N indicates number of patients; VTD, bortezomib with thalidomide plus dexamethasone; TD, thalidomide plus dexamethasone; CR. complete response; < CR, less than CR; nCR, near-CR; < nCR, less than near-CR.